Dulaglutide
Also known as: dulaglutide, LY2189265, NN9535, Trulicity
Source Dulaglutide at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Dulaglutide is a long‑acting GLP‑1 analog administered once weekly by subcutaneous injection for the treatment of type 2 diabetes mellitus.
Mechanism of Action
Agonist of the glucagon-like peptide-1 (GLP-1) receptor, enhancing glucose‑dependent insulin secretion, suppressing glucagon release, and delaying gastric emptying.
Routes of Administration
Goals & Uses
- Weight managementBody CompositionModerate
- Blood pressure reductionCardiovascularModerate
- Cardiovascular risk reductionCardiovascularHigh
- Glycemic controlDiabetesHigh
- Renal protectionRenalModerate
- Weight reductionMetabolicModerate
- Glycemic control in type 2 diabetesMetabolicHigh
Contraindications
- Personal or family history of medullary thyroid carcinomaOncologicHigh
- Diabetic ketoacidosisMetabolicHigh
- Hypersensitivity to dulaglutide or excipientsImmunologicalHigh
- Hypersensitivity to dulaglutide or any excipientImmunologicModerate
- Medullary thyroid carcinomaOncologyHigh
- Type 1 diabetes mellitusEndocrineHigh
- Multiple endocrine neoplasia type 2 (MEN 2)OncologyHigh
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)Genetic/EndocrineHigh
Adverse Effects
- Hypoglycemia (when combined with insulin or sulfonylureas)MetabolicUncommon
- PancreatitisGastrointestinalRareInflammation of the pancreas
- HypoglycemiaMetabolicUncommonAbnormally low blood glucose
- Injection site reactionsLocalUncommon
- NauseaGastrointestinalCommonFeeling of sickness or urge to vomit
- VomitingGastrointestinalCommonForceful expulsion of stomach contents
- DiarrheaGastrointestinalCommonLoose or frequent stools
Drug Interactions
- Insulin and insulin secretagogues (e.g., sulfonylureas)High
- InsulinHighMay increase risk of low blood sugar
- WarfarinModerate
- Oral medications with narrow therapeutic indexModerate
- SulfonylureasHighMay increase risk of low blood sugar
Population Constraints
- PregnancyReproductive SafetyRelative
- Pediatric patients (under 18 years)AgeRelative
- Pediatric patients (<18 years)AgeRelative
- Severe renal impairment (eGFR <15 mL/min/1.73m²)RenalRelative
- Diabetic ketoacidosisMetabolicAbsolute
- Type 1 diabetes mellitusDiabetesAbsolute
- Severe gastrointestinal diseaseGastrointestinalRelative
- Patients with prior pancreatitisPancreaticRelative
Regulatory Status
- European UnionApprovedApproved: type 2 diabetes mellitusApproved under the same dosing regimen as in the United States.
- United StatesApprovedApproved: type 2 diabetes mellitusApproved for once‑weekly subcutaneous administration.
- United KingdomApprovedApproved: type 2 diabetes mellitusApproved by the MHRA for weekly subcutaneous injection.
Approved in the United States (2014), European Union (2015) and United Kingdom (2015).
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Dulaglutide?
Dulaglutide is a long‑acting GLP‑1 analog administered once weekly by subcutaneous injection for the treatment of type 2 diabetes mellitus.
What is Dulaglutide used for?
Dulaglutide is educationally associated with: Weight management, Blood pressure reduction, Cardiovascular risk reduction, Glycemic control, Renal protection, Weight reduction, Glycemic control in type 2 diabetes. Educational only — not medical advice.
How is Dulaglutide administered?
Recorded routes of administration: Subcutaneous.
What are the potential side effects of Dulaglutide?
Reported adverse effects include: Hypoglycemia (when combined with insulin or sulfonylureas), Pancreatitis, Hypoglycemia, Injection site reactions, Nausea, Vomiting, Diarrhea. This list is not exhaustive — consult a qualified clinician.
Who should avoid Dulaglutide?
Recorded contraindications: Personal or family history of medullary thyroid carcinoma, Diabetic ketoacidosis, Hypersensitivity to dulaglutide or excipients, Hypersensitivity to dulaglutide or any excipient, Medullary thyroid carcinoma, Type 1 diabetes mellitus, Multiple endocrine neoplasia type 2 (MEN 2), Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Consult a qualified clinician before use.